Tomita, Yoshihiko
Yamamoto, Yoshiaki
Tsuchiya, Norihiko
Kanayama, Hiroomi
Eto, Masatoshi
Miyake, Hideaki
Powles, Thomas
Yoshida, Mizuki
Koide, Yuichiro
Umeyama, Yoshiko
di Pietro, Alessandra
Uemura, Hirotsugu
Clinical trials referenced in this document:
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
https://doi.org/10.1200/jco.2023.41.16_suppl.4515
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
https://doi.org/10.1136/jitc-2020-001246
665 JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma
https://doi.org/10.1136/jitc-2022-sitc2022.0665
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
https://doi.org/10.1007/s10147-021-02067-8
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.4516
Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.
https://doi.org/10.1200/jco.2024.42.4_suppl.581
Application of statistical machine learning in biomarker selection
https://doi.org/10.1038/s41598-023-45323-9
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
https://doi.org/10.1200/jco.22.01792
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).
https://doi.org/10.1200/jco.2024.42.4_suppl.600
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
https://doi.org/10.1200/jco.2023.41.6_suppl.508
Funding for this research was provided by:
Pfizer
Merck
Article History
Received: 20 September 2021
Accepted: 30 October 2021
First Online: 1 January 2022
Declarations
:
: Y. Tomita has received honoraria from Astellas Pharma, Bristol Myers Squibb, Chugai Pharma, Novartis, Ono Pharmaceutical, and Pfizer; served in a consulting or advisory role for Novartis, Ono Pharmaceutical, and Taiho Pharmaceutical; and received research funding from Astellas Pharma, AstraZeneca, Chugai Pharma, Eisai, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Takeda. Y. Yamamoto reports no disclosures. N. Tsuchiya has received honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Janssen, Merck & Co., MSD, Novartis, Pfizer, Sanofi, and Takeda and received research funding from Pfizer and Takeda. H. Kanayama has received research funding from Astellas Pharma, Fujifilm, Kissei Pharmaceutical, MSD KK, Nihon Medi-Physics, Ono Pharmaceutical, Taiho Pharmaceutical, and Takeda. M. Eto has served in a consulting or advisory role for AstraZeneca, Bristol Myers Squibb, Chugai Pharma, Eisai, Johnson & Johnson, Merck, Olympas, Ono Pharmaceutical, and Pfizer; has provided speakers services for Bristol Myers Squibb, Chugai Pharma, Janssen, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Takeda; and received research funding from Astellas Pharma, Bayer, Kissei Pharmaceutical, Ono Pharmaceutical, Sanofi, and Takeda. H. Miyake has received honoraria and research funding from and served in a consulting or advisory role for Pfizer. T. Powles has received honoraria and research funding from and served in a consulting or advisory role for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Exelixis, Ipsen, Johnson & Johnson, Merck & Co., MSD, Novartis, Pfizer, Seattle Genetics, and Roche; has received honoraria from and served in a consulting or advisory role for Incyte; and has received travel and accommodation expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. M. Yoshida reports employment at Pfizer R&D Japan. Y. Koide reports employment at Pfizer R&D Japan and owns Pfizer stock. Y. Umeyama reports employment at Pfizer R&D Japan and owns Pfizer stock. A. di Pietro reports employment at Pfizer and owns Pfizer stock. H. Uemura has provided speaker services for Bayer, Bristol Myers Squibb, Janssen, MSD, and Pfizer and has received research funding from Astellas Pharma, AstraZeneca, Daiichi Sankyo, Kissei Pharmaceutical, Ono Pharmaceutical, Sanofi, and Takeda.